Vico Therapeutics Secures Nearly $71M in Series B Funding to Bolster Clinical Programs - Next Digital Health

Vico Therapeutics B.V, a clinical-stage genetic medicines company focusing on the development of novel therapies for severe neurological illnesses, has secured €65.8 million ($70.7 million) in Series B financing to advance lead clinical programs, Seroba announced on Monday, June 24, 2024. Co-founded by Luc Dochez and Josh Mandel-Brehm, the startup’s latest financing round was spearheaded Vico Therapeutics will use the additional capital to advance its clinical programs and grow its portfolio of novel therapies for severe neurological illnesses.
read more..